Table 1. Adverse events by treatment phase and study arm (safety population, all patients who received at least one dose of study drug)

Adverse event	From first dose of study drug to 18 months after first dose		From 18 months after first dose of study drug to end of study[a]	
	Chemotherapy alone (*N* = 1271)	Chemotherapy + bevacizumab (*N* = 1288)	Chemotherapy alone (*N* = 1271)	Chemotherapy + bevacizumab (*N* = 1288)
Any adverse event, *N* (%)	1252 (98.5)	1274 (98.9)	173 (13.6)	200 (15.5)
Grade ≥ 3 adverse event, *N* (%)	722 (56.8)	924 (71.7)	58 (4.6)	58 (4.5)
Grade 5 adverse event, *N* (%)	3 (0.2)	4 (0.3)	1 (0.1)[b]	1 (0.1)[c]

Grade ≥ 3 adverse event of special interest for bevacizumab, *N* (%)	499 (39.3)	687 (53.3)	9 (0.7)	9 (0.7)
Any serious adverse event, *N* (%)	250 (19.7)	379 (29.4)	48 (3.8)	45 (3.5)

[a]None of the patients was receiving study therapy during this period; consequently there were no adverse events leading to discontinuation of study therapy.

[b]Hypoxic-ischemic encephalopathy.

[c]Cerebrovascular accident.